Pee Safe Secures $32M for Profitable Expansion into New Wellness Frontiers

CONSUMER-PRODUCTS
Whalesbook Logo
AuthorKavya Nair|Published at:
Pee Safe Secures $32M for Profitable Expansion into New Wellness Frontiers
Overview

Pee Safe has secured $32 million in Series C funding, led by OrbiMed, to accelerate its expansion in offline retail and quick commerce. The women's hygiene and wellness brand, currently generating over ₹150 crore in annualized revenue and operating profitably, plans to deepen its market penetration across India and internationally. A key strategic focus includes expanding its product portfolio into the menopause-related category, leveraging a favorable regulatory environment and growing consumer demand for comprehensive women's health solutions.

Strategic Expansion Fueled by Profitable Growth

Pee Safe's recent $32 million Series C funding round, spearheaded by global healthcare investor OrbiMed, signals a strategic pivot towards aggressive physical retail expansion and deepened quick commerce integration. This capital infusion is earmarked not merely for scale, but for profitable growth, a rarity in India's competitive D2C landscape. The company, which reported ₹82 crore in revenue for FY25 and significantly reduced losses to ₹4 crore, aims to bolster its presence from approximately 100 cities to deeper penetration within existing markets, targeting over 5,000 retail outlets per city. Investment will also target expanding its on-ground sales force to fortify general trade, modern trade, and pharmacy channels.

Tapping New Demographics and Brand Building

Beyond expanding its established product lines in feminine and intimate hygiene, Pee Safe is strategically positioning itself to address a previously underserved market segment: menopause-related wellness. This move into categories like perimenopause offerings taps into a demographic shift and growing awareness, aligning with a broader trend of comprehensive women's health solutions. Historically, brand building has been a secondary focus for Pee Safe, but the company now intends to significantly ramp up investment in this area to enhance consumer engagement and market awareness. This follows a period where the brand achieved a 100% compound annual growth rate in the five years preceding its 2023 Series B funding.

Regulatory Tailwinds and Market Dynamics

The company's growth trajectory is buoyed by favorable regulatory shifts, notably the Supreme Court's recent declaration of menstrual hygiene as a fundamental right. This ruling is expected to accelerate penetration rates for menstrual hygiene products, which have already risen from below 20% in 2017 to an estimated 30-35%. Pee Safe operates within a burgeoning Indian women's health market projected to reach $2.5 billion by 2030, with menopause being a high-growth segment. While quick commerce continues to be a vital distribution channel, rapid expansion in this sector has also attracted scrutiny regarding hygiene standards across dark stores.

Competitive Landscape and Future Outlook

Pee Safe competes in a dynamic market against established players like P&G's Whisper and Johnson & Johnson's Stayfree, as well as emerging D2C brands such as Sirona Hygiene, Nua, and Healthfab. Marico's recent acquisition of a 60% stake in Cosmix Wellness in early February 2026 highlights consolidation and strategic investment in the wellness sector. Despite Pee Safe's recent financial performance showing reduced losses and an annualized revenue run rate exceeding ₹150 crore, its ROCE and EBITDA margins remain in negative territory. Looking ahead, Pee Safe targets a ₹500 crore topline within three years, emphasizing sustained EBITDA positivity. The company's international presence spans 23 markets, with the Middle East and Saudi Arabia showing notable growth, positioning it for continued global expansion.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.